BMS Just Paid $1.5 Billion for a Company With Zero Approved Drugs
Bristol Myers Squibb is dropping $1.5 billion in cash on Orbital Therapeutics, a preclinical-stage startup with zero approved drugs and zero revenue. The bet says everything about Big Pharma's platform fever and the desperate race to fill patent cliffs.
A Preclinical Bet With a 10-Figure Price Tag
Orbital Therapeutics has never run a clinical trial. It has no approved drugs, no revenue, and no Phase 1 data. And Bristol Myers Squibb just agreed to buy it for $1.5 billion in cash.
That's not a typo. BMS is writing a check with nine zeros for a Cambridge, Massachusetts startup whose lead program hasn't even reached human testing yet. The deal tells you everything about where Big Pharma's head is right now: the future is worth more than the present, and the right platform is worth more than most products.
So what exactly is BMS buying?
The RNA Factory That Caught BMS's Eye
Orbital Therapeutics spun out of Beam Therapeutics in 2022, co-founded by John Maraganore, the former CEO of Alnylam Pharmaceuticals (the company that basically invented RNA interference drugs). The founding pedigree alone is the biotech equivalent of a Michelin-starred chef opening a new restaurant: you don't need to see the menu to know it'll be interesting.
Orbital's core technology combines three things: circular and linear RNA engineering, advanced lipid nanoparticle (LNP) delivery (the tiny fat bubbles that carry RNA into your cells), and AI-driven drug design. Think of it as a programmable medicine factory. Instead of building one drug at a time, the platform can theoretically crank out therapies across autoimmune disease, oncology, vaccines, and more.
The crown jewel is OTX-201, a preclinical candidate that attempts something genuinely wild. It's an "in vivo CAR-T" therapy, which means it tries to reprogram your immune cells inside your body using circular RNA delivered by targeted lipid nanoparticles. Traditional CAR-T therapy requires extracting a patient's cells, engineering them in a lab, and infusing them back. It's effective but expensive, slow, and logistically brutal. OTX-201 wants to skip all that by doing the engineering in place, like renovating a house while someone's still living in it.
The initial target? like lupus and rheumatoid arthritis.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
B-cell-driven autoimmune diseases
Follow the Money (All of It)
Orbital raised a massive $270 million Series A in April 2023, led by ARCH Venture Partners with participation from a16z Bio + Health, Abu Dhabi Growth Fund, Redmile Group, and a roster of other heavyweight investors. One private-market estimate pegged the company's post-Series A valuation at roughly $706 million.
That means BMS is paying about 2x that estimated Series A valuation for a company that's still in preclinical development. Generous? Maybe. But in the current M&A climate, it's almost modest.
Consider the context: by mid-2026, aggregate biopharma M&A value had already hit $130 billion, nearly matching the entire 2025 total of $133 billion. The average take-out premium for U.S.-listed therapeutics biotechs in the first half of 2026 was a staggering 82%, according to Bank of America. Pharma companies are spending like tourists on the last day of vacation, desperate to fill looming patent cliffs.
BMS's Shopping Spree Has a Pattern
This isn't BMS's first trip to the biotech mall. The company has been on a deliberate acquisition tear, snapping up Mirati (oncology), Karuna (neuroscience), and RayzeBio (radiopharmaceuticals) in 2024. Each deal followed the same playbook: buy a smaller company with a focused platform, plug it into BMS's existing therapeutic franchises, and hope the combined firepower extends the growth runway.
Orbital fits the template perfectly. BMS already has a cell therapy franchise (it owns the CAR-T pioneer Juno Therapeutics legacy through its Celgene acquisition). Adding Orbital's in vivo RNA approach could let BMS leapfrog the logistical nightmares of traditional CAR-T, potentially making immunotherapy accessible to far more patients.
BMS described the acquisition as a way to "diversify and strengthen its cell therapy portfolio." Translation: they're betting that the next generation of cell therapy won't require a cell therapy manufacturing plant.
Wall Street Shrugged
The market reaction was, to put it politely, underwhelmed. BMO Capital Markets said it was "looking for more" before getting excited about BMS's turnaround story. The firm acknowledged the science was interesting but raised a fair concern: the logistical burden of cell therapies and the availability of competing treatments could limit in vivo CAR-T to only the most severe autoimmune patients, capping its commercial ceiling.
The broader analyst backdrop didn't help either. Morgan Stanley had an Underweight rating on BMY around the same period, and Leerink Partners had recently downgraded the stock to Market Perform. The Orbital deal, whatever its long-term promise, didn't move the needle on Wall Street's cautious BMS thesis.
And honestly? That skepticism isn't unreasonable. OTX-201 is preclinical. "Preclinical" in drug development is like having a screenplay before you've cast a single actor: there's a long, expensive, failure-prone journey between here and a blockbuster. Most preclinical candidates never make it to approval.
The Bigger Picture: Platform Fever
Zoom out, and the Orbital deal is really a symptom of something larger. Big Pharma is in the middle of a platform acquisition frenzy. Companies like Johnson & Johnson ($14.6 billion for Intra-Cellular Therapies), Merck ($10 billion for Verona Pharma), and Gilead ($7.8 billion for Arcellx) have all made splashy deals in 2025 and 2026.
The logic is consistent across every transaction. Patent cliffs are coming; blockbuster drugs will lose exclusivity; and internal R&D alone can't fill the gap fast enough. So pharma is buying platforms that offer both an immediate pipeline fix and optionality for follow-on programs. It's like buying a bakery not just for today's bread, but for every recipe the ovens could ever produce.
Orbital, with its programmable RNA platform spanning autoimmune disease, oncology, vaccines, and protein replacement, checks the optionality box emphatically. Whether the science delivers is another question entirely.
The Bottom Line
BMS is paying $1.5 billion for a vision of the future: a world where CAR-T therapy doesn't require a factory, where RNA can be programmed like software, and where one platform can spawn dozens of therapies. It's a bold bet on a company with zero clinical data, backed by a founding team with a spectacular track record.
The deal is subject to customary closing conditions, including Hart-Scott-Rodino antitrust clearance. BMS and Orbital will operate independently until it closes.
If OTX-201 works, this could look like the steal of the decade. If it doesn't, it'll be a $1.5 billion reminder that in biotech, a beautiful platform and a beautiful product are two very different things.
5 min read
Novartis Just Pulled the Plug on Fabhalta's Biggest Ambition
Novartis quietly killed its mid-stage Fabhalta trial in lupus nephritis, citing only "strategic considerations." The $505 million drug is thriving in other kidney diseases, but its biggest expansion play just evaporated, and the company isn't explaining why.
